



## RUSSELL M. JAFFE, MD, PH.D., CCN, NACB

Dr. Russell M. Jaffe is Lab Director of **ELISA/ACT Biotechnologies LLC** and Fellow of the Health Studies Collegium. Through his expertise in non-invasive studies of cells, he developed novel tests for blood platelet survival, fibrinogen survival, platelet aggregation, and lymphocyte response (LRA by ELISA/ACT®). He also developed the first test for traces of blood in stool that is not made falsely negative by ascorbate (vitamin C). Dr. Jaffe received his BS, Ph.D., and MD from the Boston University School of Medicine in 1972. He completed residency training in clinical chemistry at the National Institutes of Health (1973 - 1979) and is board certified in Clinical Pathology and in Chemical Pathology. Dr. Jaffe is the recipient of the Merck, Sharp & Dohm Excellence in Research Award, the J.D. Lane Award, and the U.S.P.H.S. Meritorious Service Award. He was also named an International Scientist of the Year (2003) by the International Biographical Commission for his contributions to Medicine, Biochemistry, and Clinical Immunology. Dr. Jaffe teaches and lectures widely on the causes and consequences of immune defense and repair function in health and disease. His research interests focus on outcome studies based on effective, comprehensive care guidelines and practice parameters.

### SELECTED BIBLIOGRAPHY

Franzblau C, Faris B, Salcedo B, Jaffe R, and Crombie G. Chemistry and biosynthesis of crosslinks in elastin. *Chemistry and molecular biology of the extra cellular matrix*, ed. Balazas. Academic Press 1970; pp. 617-641.

Jaffe R and Deykin D. Evidence for the structural requirements for the aggregation of platelets by collagen. *J Clin Invest* 1974; 53:875-883.

Jaffe R and Deykin D. Proceedings: Bindings of collagen to platelets. *Throm Diath Haemorrh* September 1975; 34(1):330-32.

Jaffe R, Kasten B, MacLowry JD, and Young D. False negative occult blood tests caused by ascorbic acid. *Ann Int Med* 1975; 83:824-826.

Jaffe R. Platelet interaction with connective tissue. Physiological reaction of blood platelets, ed. Gordon. *Elsevier* 1976; pp. 261-292.

Jaffe R. The science of wellness medicine. *Proceedings: 2nd international symposium on human functioning*. Wichita: Biosynergetics Institute, 1978.

Jaffe R and Zierdt W. An occult blood test procedure not subject to inhibition by reducing substances. *J Lab Clin Med* 1978; 93:879-886.

Pitas R, Nelson C, Jaffe R, and Mahley R. 15, 1-Tetracosadienoic acid content of sphingolipids for platelets and erythrocytes of animals fed diets high in saturated or polyunsaturated fats. *Lipids* 1978; 13:551-6.

Jaffe R and Bell I. Ecological factors in learning and behavioral disorders. *The Osteopathic Physician* 1980; 47(3):25-33.

Jaffe R. *HSC information handbook for use with your immune enhancements program*. Health Studies Collegium, Thirteenth Edition, 1987-93.

Jaffe R. *Immune reconstitution: A programmatic approach*. Health Studies Collegium, 1989.

Jaffe R and Kruesi OR. The biological-immunology window: A molecular view of psychiatric case management. *J Applied Nutr* 1993; 44(2):1-15.

Jaffe R. Tryptophan update: Helpful adjunct innocent bystander. *J Nutr Med* 1994; 4:133-139.

Jaffe R. A novel treatment for fibromyalgia improves clinical outcomes in a community-based study. *J Musculoskeletal Pain* 1998; 6(2):133-149.

Jaffe R. Autoimmunity: Clinical relevance of biological response modifiers in diagnosis, treatment, and testing, Part I. *Intl J Integrative Med* 2000; 2(2):16-22.

Jaffe R. Autoimmunity: Clinical relevance of biological response modifiers in diagnosis, treatment, and testing, Part II. *Intl J Integrative Med* 2000; 2(4):58-65.

Jaffe R and Brown S. Acid-Alkaline balance and its effect on bone health. *Intl J Integrative Med* 2000; 2 (6):7-18.

Jaffe, R. *First Line Comprehensive Care. Part I: Chronic Autoimmune Disease Management by Causes Rather than Symptomatic Consequences*. Seminars in Integrative Medicine 2005 (Jun); 3 (2): 44-60.

Jaffe, R. *First Line Comprehensive Care. Part II: Anthropogenic Xenobiotics in Functional Medicine. Managing Persisting Bioaccumulating Pollutants: Toxic Minerals, Biocides, Hormone*

*Mimics, Solvents, and Chemical Disruptors*. Seminars in Integrative Medicine 2005 (Sep) 3; (3): 79-92.

Jaffe, R. Functional Lab Tests to Evaluate Immune Competencies in Chronic Illness and Chronic Infection: Part 1. *Townsend Letter for Doctors and Patients* 2006; Jan: 87-89.

Jaffe, R. Functional Lab Tests to Evaluate Immune Competencies in Chronic Illness and Chronic Infection: Part 2. *Townsend Letter for Doctors and Patients* 2006; Feb/Mar: 107-109.

Jaffe, R, Nash R, Ash, R, Schwartz, N, Corish, R, Born, T, Lazarus, H. Healthcare transparency: Opportunity or mirage. *J Management Development* 2006; 25 (10): 981-995.

Jaffe R, Mani J, DeVane J, Mani H. Tolerance loss in diabetics: Association with foreign antigen exposure. *Diabetic Medicine: A Journal of the British Diabetic Association* 2006 Aug;23(8): 924-5.

Jaffe, R, Nash R, Ash, R, Schwartz, N, Corish, R, Born, T, Lazarus, H. An equation of health: Role of transparency and opacity in developing healthcare efficacy measures and metrics. *J Management Development* 2007; 26 (5): 441-458.

Jaffe, R. First-Line Comprehensive Care III Update on Immune System Lab Tests for Fibromyalgia-Chronic Fatigue-Metabolic Syndrome: Continuum of Treatment-Resistant Pain and Fatigue: Optimum Clinical Management Improves Outcomes and Reduces Risks and Treatment Complications as Supported by New Data. *Townsend Letter for Doctors and Patients* 2008; Jan: 87-94.

Jaffe, R, Nash R, Ash, R, Schwartz, N, Corish, R, Lazarus, H. Role of transparency in managing outcome successes: Causes and 'end use / last cost' as decision guides. *J Management Development* 2008; 27 (10): 1086-1114.

Jaffe, R. Functional lab tests to evaluate immune competencies in chronic illness and chronic infection: Part 3. *Townsend Letter for Doctors and Patients* 2009; Jan:80-90.

Jaffe R. Food Reactivities: Diagnosing and Treating Food Allergies, Intolerances, and Celiac Disease in *Food and Nutrients in Disease Management*. Edited by Ingrid Kohlstadt, CRC Press, Feb 2009: 241-255.

Jaffe R. Immune Defense and Repair Systems in Biologic Medicine: Clinical Relevance of Biological Response Modifiers in Autoimmunity: Diagnosis, Treatment, Tests, and Interpretation (Part I). *Townsend Letter for Doctors and Patients* 2009; Oct: 82-89.

Jaffe R. Immune Defense and Repair Systems in Biologic Medicine: Clinical Relevance of Biological Response Modifiers in Autoimmunity: Diagnosis, Treatment, Tests, and Interpretation (Part II). *Townsend Letter for Doctors and Patients* 2009; Nov: 90-98.

Jaffe R. Immune Defense and Repair Systems in Biologic Medicine: Clinical Relevance of Biological Response Modifiers in Autoimmunity: Diagnosis, Treatment, Tests, and Interpretation (Part III). *Townsend Letter for Doctors and Patients* 2009; Dec: 76-80.

Jaffe R. LRA by ELISA/ACT Tests: Lymphocyte Response Assays (LRA) Are More Sensitive, Specific, Predictive, and Accurate for Determining Delayed Allergy to Foods and Chemicals: Letter to the Editor. *Townsend Letter for Doctors and Patients* 2010; Aug/Sep: 91-92.

Jaffe R. The Alkaline Way: Integrative Management of Autoimmune Conditions. *Townsend Letter for Doctors and Patients* 2010; Nov: 44-51.

Jaffe R. Diabetes as an Autoimmune-Immune Dysfunction Syndrome in *Bioactive Foods in Chronic Disease States*. Edited by Ronald Ross Watson, Elsevier, Inc. in press.



**ELISA/ACT BIOTECHNOLOGIES LLC**

109 Carpenter Drive, Suite 100, Sterling, VA 20164

phone: 703.450.2980 • 800.553.5472 • fax: 703.450.2981 • e-mail: [clientservices@ELISA/ACT.com](mailto:clientservices@ELISA/ACT.com)